Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 74

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 74
---
 including processing personal data on our behalf, we are required under GDPR and UK GDPR to enter into contractual arrangements to flow down or help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause customers to lose trust in us, which would have an adverse impact on our reputation and business. Future customers or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of future customers or other business relationships.

We may in the future be unable to retain and recruit qualified scientists, key executives and directors, key employ ees or key consultants, may delay our development efforts or otherwise harm our business.

Our future development and
prospects depend to a large degree on the experience, performance and continued service of our senior management team, including members
of our Board of Directors. We have invested in our management team at all levels. We have entered into contractual arrangements with our
directors and senior management team with the aim of securing the services of each of them. However, retention of these services or the
identification of suitable replacements cannot be guaranteed. There can be no guarantee that the services of the current directors and
senior management team will be retained, or that suitably skilled and qualified individuals can be identified and employed, which may
adversely impact our ability to develop our technologies and/or provide our services at the time requested by our customers or our ability
to market our services and technologies, and otherwise to grow our business, could be impaired. The loss of the services of any of the
directors or other members of the senior management team and the costs of recruiting replacements may have a material adverse effect on
us and our commercial and financial performance.

The ability to continue to
attract and retain employees with the appropriate expertise and skills also cannot be guaranteed. Finding and hiring any additional personnel
and replacements could be costly and might require us to grant significant equity awards or other incentive compensation, which could
adversely impact our financial results, and there can be no assurance that we will have sufficient financial resources to do so. Effective
product development and innovation, upon which our success is dependent, is in turn dependent upon attracting and retaining talented technical
and scientific personnel, who